EHA 2021 | Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee, MD, Weill Cornell Medicine, New York City, NY, shares updated data on overall survival from a Phase I/II study (NCT02649790) of single agent oral eltanexor for patients with myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs). Eltanexor is a second-generation, oral, selective inhibitor of nuclear export compound which has demonstrated anti-tumor activity and lower brain penetration than selinexor in nonclinical studies. Dr Lee reports that out of 15 patients evaluable for efficacy, the overall response rate was 53% with 47% of patients achieving marrow complete response (mCR). The overall survival for all patients was 9.9 months, and was 11.9 months for patients who achieved mCR. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
